<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134314</url>
  </required_header>
  <id_info>
    <org_study_id>C1INH (Berinert) for DGF</org_study_id>
    <secondary_id>IND15806</secondary_id>
    <nct_id>NCT02134314</nct_id>
  </id_info>
  <brief_title>C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF &amp; IRI</brief_title>
  <acronym>C1INHDGF</acronym>
  <official_title>Assessing Safety and Efficacy of Preoperative and Post-Transplant C1 Inhibitor (Berinert速) vs. Placebo in Recipients of a Renal Allograft From Deceased High Risk Donors and Its Impact on DGF and IRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high
      risk for delayed graft function (DGF) may show significant improvement in outcomes post
      transplant compared with patients that do not receive C1INH treatment. Complement activation
      has been detected in animal models and human kidneys with ischemic reperfusion injury (IRI)
      and inflammatory cell infiltrates. By blocking complement activation the investigators hope
      to improve kidney graft function post transplant in these recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early graft function has a long-term effect on graft survival. Poor early graft function and
      delayed graft function (DGF) contributes to decreased short- and long-term patient and graft
      survival, increased incidence of acute rejection, prolonged hospitalization, and higher costs
      of transplantation. Although multiple factors contribute to the impaired graft function,
      ischemia-reperfusion injury (IRI) is the underlying pathophysiology leading to poor early
      graft function and DGF. A &gt;35% incidence of DGF has remained constant over time despite
      significant improvements in immunosuppressive strategies and patient management. This may be
      due to increased use of kidneys from &quot;extended-criteria&quot; and/or non-heart-beating donors,
      where even greater rates (&gt;60%) of DGF have been reported.

      More than 96,680 people are currently waiting for a kidney transplant in the United States
      (United Network for Organ Sharing (UNOS); UNOS.org 3/22/13). Of the 15,092 kidney transplants
      performed in the US in 2011, ~11,000 (62%) were from deceased donors. Of these, approximately
      17% were from expanded-criteria donors. The USRDS reports that more than 50% of patients on
      the waiting list are willing to accept a kidney from an expanded-criteria donor (ECD) or
      donors after cardiac death (DCD).

      From the investigators previous studies with C1INH (Berinert速) for prevention of antibody
      mediated rejection (ABMR), the investigators noted that no patients developed ABMR during
      treatment with C1INH, the investigators also noted a near significant reduction in DGF due to
      IRI (ClinicalTrials.gov(NCT01134510), FDA Investigational New Drug (IND#): 14363). These
      findings suggest an important role for complement in the mediation of IRI and that inhibition
      of early complement activation using C1INH in patients receiving at risk kidneys for IRI
      should reduce this costly and often devastating complication of kidney transplantation. In
      addition, numerous other studies in animal models have shown dramatic improvements in IRI
      models with the use of C1INH. Complement activation is detectable in animal and in human
      kidneys models after IRI and experimental data suggests that use of C1INH prior to induction
      of IRI significantly reduces IRI as well as inflammatory cell infiltrates. Based on this, the
      investigators hypothesize that the use of C1INH in patients receiving deceased donor (DD)
      kidney transplants with high risk for DGF will show significant reductions in DGF and
      improved outcomes post-transplant compared with patients receiving DD transplants who do not
      receive C1INH treatment. Here, the investigators propose to investigate the application of
      pre-operative and post-transplant doses of C1INH (Berinert速) vs. placebo in adult subjects
      receiving a DD renal allograft considered at high-risk for IRI and DGF. The investigators
      hypothesize that C1INH treated patients will demonstrate improved function of the kidney
      allograft compared to placebo, with equivalence in safety. The primary objectives of this
      study are: Using a double blinded, placebo controlled format, the investigators will:

      1. Evaluate and compare the safety of C1INH (50 units/kilogram, round to the nearest 500
      unit) administered pre-transplant and 24 hrs post-transplant in recipients of kidney
      allografts from high risk for IRI deceased donors.

      The secondary objectives are to:

        1. On the basis of safety and efficacy, determine appropriate Berinert速 study dose for
           Phase III investigation, and

        2. Determine appropriate endpoint choice for Phase III investigation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 13, 2017</completion_date>
  <primary_completion_date type="Actual">March 13, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Enrolled With Serum Creatinine &gt;3mg/dL on Postoperative Day 5.</measure>
    <time_frame>First 7 days post-transplant</time_frame>
    <description>Number of participants in the C1INH and placebo groups with serum creatinine &gt;3mg/dL on postoperative day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Enrolled Who Require at Least One Session of Dialysis in the First 7 Days Post Transplant.</measure>
    <time_frame>First 7 days post-transplant</time_frame>
    <description>The proportion of patients enrolled who require at least one session of dialysis in the first 7 days post transplant (excluding those who are dialyzed for hyperkalemia).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Serum Creatinine Reduction Ratio of &lt; 30% From 24 to 48 Hours Post-transplant.</measure>
    <time_frame>First 7 days post-transplant</time_frame>
    <description>Number of patients in the C1INH and placebo groups with serum creatinine reduction of &lt; 30% from 24 to 48 hours post-transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Dialysis Sessions Per Patient in the First 7 Days Post Transplant.</measure>
    <time_frame>First 7 days post-transplant</time_frame>
    <description>Mean quantity of dialysis sessions per patient in the first 7 days post transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>Up to 90 days post-transplant</time_frame>
    <description>Mean serum creatinine on day 90 in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Clearance</measure>
    <time_frame>Up to 90 days post-transplant</time_frame>
    <description>Creatinine clearance calculated based on serum creatinine, milliliters per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h Urine Output</measure>
    <time_frame>24 hours post-transplant</time_frame>
    <description>24 hour urine output post-transplantation measured in milliliters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Patients on Dialysis</measure>
    <time_frame>15 to 30 days post-transplantation</time_frame>
    <description>Mean number of patients on dialysis at 15 to 30 days post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Delayed Graft Function (DGF) (Categorized by DGF Scale)</measure>
    <time_frame>First 7 days post-transplant</time_frame>
    <description>DGF Scale:
Grade 1 - immediate urine production and no need for dialysis with creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation &gt;70%
Grade 2 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation of &gt;70% with need for dialysis
Grade 3 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation &lt;70% with no need for dialysis
Grade 4 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation of &lt;70% with need for dialysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Incidence of Serious Adverse Events</measure>
    <time_frame>Up to 9 months post-transplant</time_frame>
    <description>Overall incidence of serious adverse events in the C1INH and placebo groups, number of events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Survival</measure>
    <time_frame>Up to 90 days post-transplant</time_frame>
    <description>Patient survival at 90 days post-transplantation</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Acute Cellular Rejection (ACR)</measure>
    <time_frame>Up to 90 days post-transplant</time_frame>
    <description>Number of acute cellular and antibody mediated rejection episodes by day 90.</description>
  </other_outcome>
  <other_outcome>
    <measure>Graft Survival</measure>
    <time_frame>Day 90 Post-transplant</time_frame>
    <description>Number of Participants with Graft Survival at 90 Days Post-Transplant</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Kidney Failure</condition>
  <condition>Delayed Graft Function</condition>
  <condition>Ischemic Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>C1-Inhibitor (Berinert) (Human) (C1INH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1 Esterase Inhibitor</intervention_name>
    <description>C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses</description>
    <arm_group_label>C1-Inhibitor (Berinert) (Human) (C1INH)</arm_group_label>
    <other_name>Berinert (C1INH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Normal Saline (0.9%NaCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 yrs of age; recipient of ECD/DCD/ECD&amp;DCD with risk index 3-8 for DGF based on
             specific criteria

          -  recipient who are ABO compatible with donor allograft

          -  pretransplant with meningococcal vaccination

          -  understand and sign a written consent prior to any study specific procedure.

        Risk index (minimum 3- maximum 8):

        DGF scale: Donor Age (&lt;40yr = 0, 41-49yr = 1, 50-54yr = 2, 55-59yr = 3, &gt;60yr=6), Cold
        Ischemia Time (0-12= 0, 13-18=1, 19-24=2, 24-30=3, 31-36=4, &gt;37=6; Recipient Race (nonblack
        = 0, black =1); Donor death due to Cerebrovascular Accident (CVA) (donor age &lt;50yrs = 0,
        donor age &gt;50yrs = 3).

        Exclusion Criteria:

          -  patients with known prothrombotic disorder (e.g. factor V leiden)

          -  history of thrombosis or hypercoagulable state excluding access clotting

          -  history of administration of C1INH containing products or recombinant C1INH within 15
             days prior to study entry

          -  patients with known contraindication to treatment with C1INH

          -  patients with abnormal coagulation function (INR &gt;2, partial thromboplastin time (PTT)
             &gt; 50, platelets &lt;80,000)

          -  who are not on anti-coagulation

          -  patients with known active presence of malignancies

          -  Polymerase chain reaction (PCR) positive for hep B/hep C/or HIV

          -  preemptive kidney transplantation recipient

          -  recipients of multi-organ transplants (kidney and any other organ)

          -  recipients of kidney allograft from DD who: cold ischemia time (CIT) &lt;18h, terminal
             serum creatinine &lt;/= 1mg/dl, recipient of kidney allograft that was on pump
             preservation for any period prior to transplantation, recipient of kidney allograft
             from a living donor, female subject who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley C Jordan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center, Los Angeles, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashley Vo, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Cedars-Sinai Medical Center, Los Angeles, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cedars-sinai.edu/Patients/Quality-Measures/Clinical-Areas/Transplantation/Kidney-Transplantation.aspx</url>
    <description>Cedars Sinai Medical Center Kidney Transplantation</description>
  </link>
  <link>
    <url>http://www.berinert.com/</url>
    <description>Information of C1INH (Berinert)</description>
  </link>
  <reference>
    <citation>Dalle Lucca JJ, Li Y, Simovic M, Pusateri AE, Falabella M, Dubick MA, Tsokos GC. Effects of C1 inhibitor on tissue damage in a porcine model of controlled hemorrhage. Shock. 2012 Jul;38(1):82-91. doi: 10.1097/SHK.0b013e31825a3522.</citation>
    <PMID>22683724</PMID>
  </reference>
  <reference>
    <citation>Pascual J, Zamora J, Pirsch JD. A systematic review of kidney transplantation from expanded criteria donors. Am J Kidney Dis. 2008 Sep;52(3):553-86. doi: 10.1053/j.ajkd.2008.06.005. Review.</citation>
    <PMID>18725015</PMID>
  </reference>
  <reference>
    <citation>Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V, Rossini M, Divella C, Battaglia M, Lucarelli G, Annunziata G, Palazzo S, Selvaggi FP, Staffieri F, Crovace A, Daha MR, Mannesse M, van Wetering S, Paolo Schena F, Grandaliano G. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010 Apr;176(4):1648-59. doi: 10.2353/ajpath.2010.090276. Epub 2010 Feb 11.</citation>
    <PMID>20150432</PMID>
  </reference>
  <reference>
    <citation>Giral-Classe M, Hourmant M, Cantarovich D, Dantal J, Blancho G, Daguin P, Ancelet D, Soulillou JP. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int. 1998 Sep;54(3):972-8.</citation>
    <PMID>9734625</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <results_first_submitted>March 13, 2018</results_first_submitted>
  <results_first_submitted_qc>June 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2018</results_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Stanley Jordan, MD</investigator_full_name>
    <investigator_title>Medical Director, Kidney Transplant Program; Director of Transplant Immunology and Nephrology</investigator_title>
  </responsible_party>
  <keyword>ESRD (End Stage Renal Disease)</keyword>
  <keyword>CKD (Chronic Kidney Disease)</keyword>
  <keyword>Kidney Transplant</keyword>
  <keyword>ECD</keyword>
  <keyword>delayed graft function</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>expanded-criteria donor</keyword>
  <keyword>end stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1s</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 25, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02134314/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
          <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg intravenous infusion administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
          <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg intravenous infusion administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.66" spread="7.74"/>
                    <measurement group_id="B2" value="58.14" spread="11.18"/>
                    <measurement group_id="B3" value="57.9" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Patients were categorized as either African American or not African American.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.17" spread="12.35"/>
                    <measurement group_id="B2" value="45.57" spread="15.69"/>
                    <measurement group_id="B3" value="47.37" spread="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.78" spread="1.44"/>
                    <measurement group_id="B2" value="1.75" spread="1.92"/>
                    <measurement group_id="B3" value="1.77" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor DCD Cause of Death</title>
          <description>The kidney transplant donor was a Donor after Cardiac Death (DCD).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor KDPI</title>
          <description>Mean kidney transplant donor Kidney Donor Profile Index (KDPI), shown as a percentage. Kidneys with a high KDPI are associated with higher rates of DGF and worse long term survival in comparison to those with a low KDPI. In this study, the eligibility criteria included recipients of kidney allografts from ECD (or KDPI &gt;/= 85) donors. A KDPI &gt;/= 85 confers the highest risk for DGF and allograft loss.</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.71" spread="21.83"/>
                    <measurement group_id="B2" value="64.63" spread="25.39"/>
                    <measurement group_id="B3" value="66.17" spread="23.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor KDPI equal to or greater than 85%</title>
          <description>The donor's Kidney Donor Profile Index (KDPI) was equal to or greater than 85%. Mean kidney transplant donor Kidney Donor Profile Index (KDPI), shown as a percentage. Kidneys with a high KDPI are associated with higher rates of DGF and worse long term survival in comparison to those with a low KDPI. In this study, the eligibility criteria included recipients of kidney allografts from ECD (or KDPI &gt;/= 85) donors. A KDPI &gt;/= 85 confers the highest risk for DGF and allograft loss.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transplant Cold Ischemia Time</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.27" spread="4.89"/>
                    <measurement group_id="B2" value="19.84" spread="6.10"/>
                    <measurement group_id="B3" value="19.06" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-HLA DSA</title>
          <description>Anti-Human leukocyte antigen (HLA) Donor Specific Antibody (DSA)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HLA Class I Antibodies Present</title>
          <description>Human leukocyte antigen (HLA) Class I Antibodies</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HLA Class II Antibodies Present</title>
          <description>Human leukocyte antigen (HLA) Class II Antibodies</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment with Thymoglobulin at transplantation</title>
          <description>Patients who received thymoglobulin as an induction agent at transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment with Alemtuzumab at transplantation</title>
          <description>Patients who received alemtuzumab (Campath) as an induction agent at transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Enrolled With Serum Creatinine &gt;3mg/dL on Postoperative Day 5.</title>
        <description>Number of participants in the C1INH and placebo groups with serum creatinine &gt;3mg/dL on postoperative day 5</description>
        <time_frame>First 7 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg intravenous infusion administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Enrolled With Serum Creatinine &gt;3mg/dL on Postoperative Day 5.</title>
          <description>Number of participants in the C1INH and placebo groups with serum creatinine &gt;3mg/dL on postoperative day 5</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Enrolled Who Require at Least One Session of Dialysis in the First 7 Days Post Transplant.</title>
        <description>The proportion of patients enrolled who require at least one session of dialysis in the first 7 days post transplant (excluding those who are dialyzed for hyperkalemia).</description>
        <time_frame>First 7 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Enrolled Who Require at Least One Session of Dialysis in the First 7 Days Post Transplant.</title>
          <description>The proportion of patients enrolled who require at least one session of dialysis in the first 7 days post transplant (excluding those who are dialyzed for hyperkalemia).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Serum Creatinine Reduction Ratio of &lt; 30% From 24 to 48 Hours Post-transplant.</title>
        <description>Number of patients in the C1INH and placebo groups with serum creatinine reduction of &lt; 30% from 24 to 48 hours post-transplant.</description>
        <time_frame>First 7 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serum Creatinine Reduction Ratio of &lt; 30% From 24 to 48 Hours Post-transplant.</title>
          <description>Number of patients in the C1INH and placebo groups with serum creatinine reduction of &lt; 30% from 24 to 48 hours post-transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Dialysis Sessions Per Patient in the First 7 Days Post Transplant.</title>
        <description>Mean quantity of dialysis sessions per patient in the first 7 days post transplant.</description>
        <time_frame>First 7 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dialysis Sessions Per Patient in the First 7 Days Post Transplant.</title>
          <description>Mean quantity of dialysis sessions per patient in the first 7 days post transplant.</description>
          <units>dialysis sessions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.22"/>
                    <measurement group_id="O2" value="1.54" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine</title>
        <description>Mean serum creatinine on day 90 in mg/dL</description>
        <time_frame>Up to 90 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine</title>
          <description>Mean serum creatinine on day 90 in mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.317"/>
                    <measurement group_id="O2" value="1.7" spread="1.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Clearance</title>
        <description>Creatinine clearance calculated based on serum creatinine, milliliters per minute.</description>
        <time_frame>Up to 90 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Clearance</title>
          <description>Creatinine clearance calculated based on serum creatinine, milliliters per minute.</description>
          <units>ml/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="15.558"/>
                    <measurement group_id="O2" value="51.2" spread="17.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24h Urine Output</title>
        <description>24 hour urine output post-transplantation measured in milliliters</description>
        <time_frame>24 hours post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>24h Urine Output</title>
          <description>24 hour urine output post-transplantation measured in milliliters</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="873.5" spread="1257.0"/>
                    <measurement group_id="O2" value="607.8" spread="782.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Patients on Dialysis</title>
        <description>Mean number of patients on dialysis at 15 to 30 days post-transplant</description>
        <time_frame>15 to 30 days post-transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Patients on Dialysis</title>
          <description>Mean number of patients on dialysis at 15 to 30 days post-transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Delayed Graft Function (DGF) (Categorized by DGF Scale)</title>
        <description>DGF Scale:
Grade 1 - immediate urine production and no need for dialysis with creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation &gt;70%
Grade 2 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation of &gt;70% with need for dialysis
Grade 3 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation &lt;70% with no need for dialysis
Grade 4 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation of &lt;70% with need for dialysis.</description>
        <time_frame>First 7 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Delayed Graft Function (DGF) (Categorized by DGF Scale)</title>
          <description>DGF Scale:
Grade 1 - immediate urine production and no need for dialysis with creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation &gt;70%
Grade 2 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation of &gt;70% with need for dialysis
Grade 3 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation &lt;70% with no need for dialysis
Grade 4 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation of &lt;70% with need for dialysis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overall Incidence of Serious Adverse Events</title>
        <description>Overall incidence of serious adverse events in the C1INH and placebo groups, number of events.</description>
        <time_frame>Up to 9 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Incidence of Serious Adverse Events</title>
          <description>Overall incidence of serious adverse events in the C1INH and placebo groups, number of events.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Survival</title>
        <description>Patient survival at 90 days post-transplantation</description>
        <time_frame>Up to 90 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival</title>
          <description>Patient survival at 90 days post-transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Acute Cellular Rejection (ACR)</title>
        <description>Number of acute cellular and antibody mediated rejection episodes by day 90.</description>
        <time_frame>Up to 90 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Acute Cellular Rejection (ACR)</title>
          <description>Number of acute cellular and antibody mediated rejection episodes by day 90.</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Graft Survival</title>
        <description>Number of Participants with Graft Survival at 90 Days Post-Transplant</description>
        <time_frame>Day 90 Post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
            <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival</title>
          <description>Number of Participants with Graft Survival at 90 Days Post-Transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected up to 9 months post transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>C1-Inhibitor (Berinert) (Human) (C1INH)</title>
          <description>35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
C1 Esterase Inhibitor: C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
Placebo: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>A fib, shortness of breath, chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Right leg DVT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper extermity/facial swelling, SVC syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>A flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Afib/ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Non ST segment elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutropenia/Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Purulent Drainage from wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Acute Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sepsis from Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Slurred speech/weakness/fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine/edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nephrectomy due to poor perfusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urine Leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Peri-renal transplant hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flash pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspnea on exertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Generalized fatigue described by the patient</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of this study include the small sample size and single-center performance. However, the patient population was balanced between the two groups and donor organ characteristics, including implantation biopsies, were similar.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Noriko Ammerman, PharmD</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>310-248-8186</phone>
      <email>noriko.ammerman@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

